ABIOMED (NASDAQ:ABMD) was upgraded by equities researchers at BidaskClub from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Saturday.

A number of other equities research analysts also recently commented on the company. Zacks Investment Research raised ABIOMED from a “hold” rating to a “buy” rating and set a $393.00 price target for the company in a report on Monday, February 4th. BTIG Research reissued a “buy” rating and issued a $400.00 price target on shares of ABIOMED in a report on Tuesday, January 22nd. They noted that the move was a valuation call. Morgan Stanley decreased their price target on ABIOMED from $496.00 to $461.00 and set an “overweight” rating for the company in a report on Wednesday, January 2nd. Finally, ValuEngine raised ABIOMED from a “hold” rating to a “buy” rating in a report on Wednesday, November 28th. Nine investment analysts have rated the stock with a buy rating, The company has an average rating of “Buy” and an average price target of $413.71.

Shares of NASDAQ ABMD opened at $341.21 on Friday. The stock has a market capitalization of $15.29 billion, a price-to-earnings ratio of 139.27, a price-to-earnings-growth ratio of 3.45 and a beta of 0.38. ABIOMED has a fifty-two week low of $219.13 and a fifty-two week high of $459.75.

ABIOMED (NASDAQ:ABMD) last released its earnings results on Thursday, January 31st. The medical equipment provider reported $0.97 EPS for the quarter, topping the Zacks’ consensus estimate of $0.94 by $0.03. ABIOMED had a return on equity of 20.31% and a net margin of 30.12%. The firm had revenue of $200.56 million during the quarter, compared to the consensus estimate of $200.60 million. Sell-side analysts forecast that ABIOMED will post 3.61 EPS for the current year.

In related news, COO David M. Weber sold 24,000 shares of the business’s stock in a transaction that occurred on Friday, January 25th. The stock was sold at an average price of $351.47, for a total transaction of $8,435,280.00. Following the completion of the sale, the chief operating officer now directly owns 161,842 shares in the company, valued at $56,882,607.74. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Martin P. Sutter sold 5,985 shares of the business’s stock in a transaction that occurred on Wednesday, February 6th. The stock was sold at an average price of $349.49, for a total value of $2,091,697.65. Following the sale, the director now owns 212,943 shares of the company’s stock, valued at $74,421,449.07. The disclosure for this sale can be found here. Insiders sold 49,928 shares of company stock valued at $17,512,612 over the last 90 days. Company insiders own 3.50% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. grew its holdings in ABIOMED by 5.9% in the 3rd quarter. Vanguard Group Inc. now owns 4,647,227 shares of the medical equipment provider’s stock valued at $2,090,091,000 after buying an additional 260,829 shares in the last quarter. Vanguard Group Inc grew its holdings in ABIOMED by 5.9% in the 3rd quarter. Vanguard Group Inc now owns 4,647,227 shares of the medical equipment provider’s stock valued at $2,090,091,000 after buying an additional 260,829 shares in the last quarter. BlackRock Inc. grew its holdings in ABIOMED by 1.5% in the 4th quarter. BlackRock Inc. now owns 3,165,242 shares of the medical equipment provider’s stock valued at $1,028,829,000 after buying an additional 47,673 shares in the last quarter. Renaissance Technologies LLC grew its holdings in ABIOMED by 10.8% in the 3rd quarter. Renaissance Technologies LLC now owns 1,719,023 shares of the medical equipment provider’s stock valued at $773,131,000 after buying an additional 167,600 shares in the last quarter. Finally, AQR Capital Management LLC grew its holdings in ABIOMED by 193.5% in the 3rd quarter. AQR Capital Management LLC now owns 1,207,996 shares of the medical equipment provider’s stock valued at $543,297,000 after buying an additional 796,482 shares in the last quarter. Hedge funds and other institutional investors own 87.08% of the company’s stock.

About ABIOMED

ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.

Read More: What is a conference call?

Analyst Recommendations for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.